Navigation Links
Ambit Biosciences Announces Third Quarter 2013 Operating Results
Date:11/7/2013

f Ambit's drug development programs, including the submission of regulatory filings and planned discussions with regulatory bodies, plans regarding future clinical trials of quizartinib and Ambit's other drug candidates, the progress and expected timing of clinical trials, the presentation of data from clinical trials, the clinical benefits to be derived from quizartinib and Ambit's other drug candidates, the regulatory approval path for quizartinib, the strength of Ambit's balance sheet and adequacy of cash on hand, and Ambit's financial guidance.. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as  "plans," "expects," "anticipates," "hopes", "may," "will," "goal," "potential" and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Ambit's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Ambit's programs are described in additional detail in Ambit's SEC filings. All forward-looking statements contained in this press release speak only as of the date on which they were made. Ambit undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

  Ambit Biosciences CorporationSelected Financial Information Condensed Consolidated Statements of Operations(unaudited, in thou
'/>"/>

SOURCE Ambit Biosciences
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Ambit Announces Participation At 12th Annual BIO Investor Forum
2. Ambit Announces Participation At The BioCentury NewsMakers in the Biotech Industry Conference
3. Ambit Announces Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the Annual Meeting of the American Society of Clinical Oncology
4. Ambit Biosciences Files Registration Statement for Proposed Initial Public Offering
5. APAC Stem Cell Research & Therapy Market a “Growth Engine” for Region’s Scientific Ambitions Says A New Market Research Report at ReportsnReports.com
6. Astellas and Ambit Announce Data Presentations Highlighting Quizartinib at the American Society of Hematology 54th Annual Meeting
7. Ambit Biosciences to Present at Two Upcoming Investor Conferences
8. Ambit and Astellas Announce Results From Multiple Quizartinib Presentations at the 53rd Annual Meeting of the American Hematology Society
9. Ambit Biosciences Names Michael A. Martino President and Chief Executive Officer
10. Pressure BioSciences, Inc. Reports Third Quarter 2013 Financial Results and Provides Business Update
11. Juneau Biosciences Names Dr. Dinesh Patel to Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... SAN DIEGO and BETHESDA, Md. ... they are joining together with two institutes from the ... more reliable tools for bringing safer, more effective treatments ... with the National Center for Advancing Translational Sciences (NCATS) ...
(Date:1/14/2014)... Canada (PRWEB) January 14, 2014 In ... its motives and methods in product development and promotion ... the industry. This mistrust, fueled by concerns about the ... fed by reports of spectacular fines to the world’s ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
(Date:1/14/2014)... and Cardiff, UK (PRWEB) January 13, 2014 ... development leader with more than 20 years in the ... optics and photonics . Hainsey will serve as the ... to have Dr. Hainsey join SPIE as our Technology ...
Breaking Biology Technology:Organovo Announces Collaboration with National Institutes of Health 2Organovo Announces Collaboration with National Institutes of Health 3The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 2The Sunshine Act: Necessary Regulation or Unnecessary Dysregulation? New Life Science Webinar Hosted by Xtalks and IRB Services 3Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2Photonics R&D Leader Bob Hainsey Joins SPIE Technical Staff 2
... ANDS ) announced today that it will present ... on Tuesday,March 4, 2008 at 4:30 p.m. EST (1:30 ... Hotel in New York., Steve Worland, Ph.D., President ... an overview of Anadys and its two,development-stage product candidates, ...
... Vermillion, Inc.,(Nasdaq: VRML ) announced that on February ... Market LLC that indicated the Company is not in,compliance ... (i),a minimum of $2,500,000 in stockholders, equity; (ii) $35,000,000 ... net income from continuing,operations for the most recently completed ...
... Ltd., a wholly owned subsidiary of Forest Laboratories, ... and Mylan Inc. (NYSE: MYL ) have,amended ... the novel beta blocker Bystolic(TM) (nebivolol), which is,currently ... of hypertension.,The companies have agreed that Forest will ...
Cached Biology Technology:Anadys Pharmaceuticals to Present at the Susquehanna SIGnificant Options in Healthcare Conference 2Vermillion Receives NASDAQ Notice of Non-Compliance 2Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement 2Forest Laboratories, Inc. Announces Amendment to Bystolic(TM) (nebivolol) Agreement 3
(Date:4/17/2014)... State University engineer has developed a patented technique ... explosive devices. The same technique could help police ... M. and Kay L. Theede chair in engineering ... and his research team have created a template-based ... car trunks. The distance detection method called ...
(Date:4/17/2014)... release is available in German . ... pay the protection money demanded of him, he can expect ... required, however, as fear of the consequences is enough to ... in parasitic birds, which lay their eggs in other birds, ... the brood parasites take their revenge by destroying the entire ...
(Date:4/17/2014)... conditions such as heart disease, epilepsy and pain, making ... there is still much scientists do not know about ... insight into the structure of sodium channels and, specifically, ... are responsible for ,fine-tuning, the activity of the channel. ... of the Journal of Biological Chemistry . , ...
Breaking Biology News(10 mins):Patented research remotely detects nitrogen-rich explosives 2Fear of the cuckoo mafia 2Fear of the cuckoo mafia 3Structure of sodium channels different than previously believed 2
... a devastating wheat fungus isn,t threatening the state,s crops yet. ... the U.S. Department of Agriculture to keep it that way. ... leading a group of researchers to study the wheat blast ... Brazil. "We don,t know if our varieties in Kansas ...
... In the rogues, gallery of microscopic infectious agents, the prion ... both DNA and RNA, prions are believed to cause such ... and moose, mad cow disease in cattle, scrapie in sheep ... the weirdest infectious agent know to science, the prion is ...
... repair patterns may increase risk of pancreatic cancer by as ... 77 percent, depending on the genes involved, according to a ... Clinical Cancer Research , a journal of the American Association ... in late stages, and thus is resistant to most available ...
Cached Biology News:Researchers to use K-State's BSL-3 Lab for $1 million study of fungus threatening wheat crops 2Researchers to use K-State's BSL-3 Lab for $1 million study of fungus threatening wheat crops 3Common soil mineral degrades the nearly indestructible prion 2
Phospho- (Ser) 14-3-3 Binding Motif (4E2) Mouse mAb...
Rat polyclonal to acetyl Salicylic Acid ( Abpromise for all tested applications)....
Drugs and NO-drug Rat Anti-conjugated Acetyl Salicylic Acid Polyclonal Antibody...
Rabbit polyclonal to UBC12 (rating: ****) ( Abpromise for all tested applications). Antigen: Synthetic peptide: RGGYIGSTYFER, corresponding to amino acids 169-180 of UBC12 Entrez Gene ID: 90...
Biology Products: